Compare Ginkgo Bioworks Holdings Inc (DNA) vs Kinder Morgan Inc (KMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Kinder Morgan Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $8.93 (market cap $590.53M), while Kinder Morgan Inc trades at $32.27 (market cap $72.40B). The key difference: Kinder Morgan Inc is far larger — about 122.6× Ginkgo Bioworks Holdings Inc's market cap, and Kinder Morgan Inc pays a 3.61% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | KMI | |
|---|---|---|
Market Cap | $590.53M | $72.40B |
Sector | Health | Energy |
52-Week High | $16.14 | $34.31 |
52-Week Low | $5.48 | $25.84 |
Enterprise Value | $627.78M | $104.27B |
Dividend Yield | — | 3.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
KMI trades at $32.24, up 0.37% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $0.48, and revenue growth is projected to reach $17.5B in 2026. Analyst sentiment is mixed but leans positive, with 47% recommending a buy, supported by a stable dividend and a $10.1B project backlog focused on natural gas infrastructure.
The outlook for KMI is favorable, driven by rising LNG demand and contracted cash flows, though risks include commodity price volatility and high debt levels. The stock offers a solid dividend yield and growth potential from infrastructure investments, making it attractive for income and growth investors despite macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →
